Published in Blood Weekly, September 25th, 1995
Efficacy trials for experimental AIDS therapies currently determine whether the proposed treatment either improves survival or delays the appearance of AIDS-defining opportunistic infections. These endpoints take years to achieve, but provide what is currently believed to be the best way to get the best information on the benefits of the treatment being tested.
Meanwhile, people die and the backlog of new treatments and new combination therapies gets longer and longer. A better way might be to evaluate and approve...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.